Business Monitor International


France Pharmaceuticals & Healthcare Report

Published 28 May 2014

  • 121 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
France Pharmaceuticals & Healthcare Report

BMI View: Public consumption in France will decline in 2014 and 2015 as the government attempts to bring the fiscal deficit within the EU's deficit reduction target of 3.0% of GDP by 2015 - affecting expenditure on pharmaceuticals and healthcare as a part of the government's fiscal consolidation plans. However, the new government of Manuel Valls has indicated it may seek to further delay its deficit cutting commitments and this may result in the healthcare sector being a continued target of austerity, particularly as health expenditure growth for 2015, 2016 and 2017 has been capped at 2.1%, 2.0% and 1.9%, respectively and additional measures may be required to rein in spending.

Headline Expenditure Projections

  • Pharmaceuticals: EUR33.75bn (USD44.55bn) in 2013 to EUR32.93bn (USD44.12bn) in 2014; -2.4% in local currency terms and -1.0% in US dollar terms.

  • Healthcare: EUR237.64bn (USD301.80bn) in 2013 to EUR243.46bn (USD321.36bn) in 2014; +2.4% in local currency terms and 6.5% in US dollar terms.

Risk/Reward Ratings: France is ranked third out of the 15 markets in BMI's Western Europe Pharmaceutical Risk/Reward Ratings (RRR) matrix for Q314, with a composite score of 71.7 out of the maximum 100 points. The country's Reward profile remains considerably less attractive than its risk score, reinforcing our view of the country's potential due to a stronger emphasis on the regulatory environment, which we regard as a major factor affecting the business environment for drugmakers, rather than on the basis of real opportunities for higher per-capita drug consumption.

Key Trends And Developments

Aligning with our long-term view that the French government will engage in more concerted fiscal consolidation (with a heavy focus on the pharmaceuticals and healthcare sector) as a result of the country's lacklustre economic activity, In April 2014, France's new prime minister Manuel Valls unveiled details as to how the government aims to extract EUR50bn (USD69bn) in savings...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (France 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (France 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (France 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (France 2010-2018)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (France 2010-2018)
22
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (France 2010-2018)
23
France Generic Drug Market Forecast
24
Table: Generics Drug Market Indicators, Historical Data And Forecasts (France 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (France 2010-2018)
31
Pharmaceutical Trade Forecast
32
Table: Pharmaceutical Trade Data And Forecasts (France 2012-2018)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (France 2012-2018)
34
Other Healthcare Data
34
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
36
Economic Analysis
36
Macro Outlook
36
Real GDP By Expenditure Breakdown
37
Risks To Outlook
40
Table: France - Economic Activity
41
Industry Risk Reward Ratings
42
Western Europe Risk/Reward Ratings
42
France Risk/Reward Ratings
47
Rewards
47
Risks
47
Market Overview
49
Industry Trends And Developments
50
Epidemiology
50
Prescription Drugs
51
Healthcare Financing
52
Public Hospitals
54
Table: Hospital Activity, 2005-2009
55
Table: Hospital Activity in Short-Stay Units, 2009
56
Table: Diagnostic & Therapeutic Procedures Performed in Public & Private Hospitals, 2009
57
Table: Regional Ranking Of Projected Physicians, 2017
59
Table: Projected Physicians, 2012-2017
59
Table: Medical Personnel, 2005-2010
60
Generic Drugs
60
Research & Development
61
Biotechnology
63
Clinical Trials
66
Regulatory Development
68
Intellectual Property Issues
70
Pricing & Reimbursement
71
Table: France Reimbursement Categories
71
Biosimilars
74
OTC Medicines
79
Competitive Landscape
80
Pharmaceutical Sector
80
Foreign Industry
82
Pharmaceutical Distribution
83
Pharmaceutical Retail Sector
84
Company Profile
86
Sanofi
86
Servier
96
Ipsen
101
Pfizer
106
GlaxoSmithKline
109
Novartis
112
Merck & Co
115
Demographic Forecast
117
Table: France's Population By Age Group, 1990-2020 ('000)
118
Table: France's Population By Age Group, 1990-2020 (% of total)
119
Table: France's Key Population Ratios, 1990-2020
120
Table: France's Rural And Urban Population, 1990-2020
120
Glossary
121
Methodology
123
Pharmaceutical Expenditure Forecast Model
123
Healthcare Expenditure Forecast Model
123
Notes On Methodology
124
Risk/Reward Ratings Methodology
125
Ratings Overview
126
Table: Pharmaceutical Risk/Reward Ratings Indicators
126
Indicator Weightings
127

The France Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's France Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the French pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for France to test other views - a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.
  • Target business opportunities and risks in the French pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in France.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc